<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686504</url>
  </required_header>
  <id_info>
    <org_study_id>D0475C00013</org_study_id>
    <secondary_id>EudractCT 2008-000064-17</secondary_id>
    <nct_id>NCT00686504</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066</brief_title>
  <acronym>PET</acronym>
  <official_title>An Open Label, Non-randomized Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 After Oral Administration to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is carried out in order to determine the relationship between AZD2066 exposure and
      mGluR5 receptor occupancy in the brain and to demonstrate that AZD2066 can displace
      [11C]AZ12713580 from mGluR5 binding-sites in the Central Nervous System
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positron emission tomography using the radioligand radioligand [11C]AZ12713580</measure>
    <time_frame>4 times</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety and tolerability of AZD2066 by assessment of Adverse Events (AEs), vital signs measurements (blood pressure and pulse), electrocardiogram (ECG), physical examination, clinical chemistry, haematology and urinalysis.</measure>
    <time_frame>7 visits with tests for all subjects. Some tests will be done several times per visit. All tests will not be performed at every visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate pharmacokinetics of AZD2066</measure>
    <time_frame>15 times per subject. Up to 48 hours each time</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2066</intervention_name>
    <description>single dose of oral dose, 3 times per subject</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>radioligand [11C] AZ12713580</intervention_name>
    <description>single dose of iv administered 4 times per subject (3 times together with AZD2066)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent

          -  BMI (Body Mass Index) of ≥19 to ≤28 kg/m2 and weight of ≥50 to ≤100 kg

          -  Normal MRI (Magnetic Resonance Imaging) scan at visit 2

        Exclusion Criteria:

          -  History of previous or ongoing psychiatric disease or condition including psychosis,
             affective disorder, anxiety disorder, borderline state and personality disorder
             according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders

          -  History of psychotic disorder among first degree relatives (parents, siblings)

          -  History of use of antipsychotic, antidepressant or anxiolytic (anxiety treatment)
             drugs, prescribed or non-prescribed use. History of antidepressants or anxiolytics for
             non-psychiatric conditions such as pain or post-operative insomnia is allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Fransson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Astrazeneca Clinical Pharmacology Unit, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophia Bengtsson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Study Delivery, Clinical Development, Södertälje, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rolf Karlsten, MD, PhD, Medical Science Director, Emerging Analgesia</name_title>
    <organization>AstraZeneca R&amp;D Södertälje, Sweden</organization>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>PET</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>mGlu5 receptor</keyword>
  <keyword>Dose finding</keyword>
  <keyword>Analgesia/Pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

